We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02247804
Previous Study | Return to List | Next Study

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02247804
Recruitment Status : Recruiting
First Posted : September 25, 2014
Last Update Posted : June 19, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Condition or disease Intervention/treatment Phase
Glaucoma, Open-Angle Ocular Hypertension Drug: Bimatoprost sustained-release Other: Sham Drug: Timolol Drug: Timolol Vehicle (placebo) Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension
Actual Study Start Date : October 23, 2014
Estimated Primary Completion Date : November 29, 2017
Estimated Study Completion Date : May 3, 2019


Arms and Interventions

Arm Intervention/treatment
Experimental: Bimatoprost SR Dose A
Study Eye: bimatoprost sustained-release (SR) Dose A administered on Day 1, Week 16, and Week 32; timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.
Drug: Bimatoprost sustained-release
Bimatoprost sustained-release (SR) administered in the study eye on Day 1, Week 16, and Week 32.
Other: Sham
Sham administered on Day 1, Week 16, and Week 32, as per protocol.
Drug: Timolol
Timolol administered once in the morning and once in the evening for up to 20 months, as per protocol.
Other Name: TIMOPTIC®
Drug: Timolol Vehicle (placebo)
Timolol vehicle administered once in the morning and once in the evening for up to 20 months, as per protocol.
Experimental: Bimatoprost SR Dose B
Study Eye: bimatoprost SR Dose B administered on Day 1, Week 16, and Week 32; timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.
Drug: Bimatoprost sustained-release
Bimatoprost sustained-release (SR) administered in the study eye on Day 1, Week 16, and Week 32.
Other: Sham
Sham administered on Day 1, Week 16, and Week 32, as per protocol.
Drug: Timolol
Timolol administered once in the morning and once in the evening for up to 20 months, as per protocol.
Other Name: TIMOPTIC®
Drug: Timolol Vehicle (placebo)
Timolol vehicle administered once in the morning and once in the evening for up to 20 months, as per protocol.
Sham Comparator: Sham
Both Eyes: sham administered on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.
Other: Sham
Sham administered on Day 1, Week 16, and Week 32, as per protocol.
Drug: Timolol
Timolol administered once in the morning and once in the evening for up to 20 months, as per protocol.
Other Name: TIMOPTIC®


Outcome Measures

Primary Outcome Measures :
  1. Change from Baseline in Intraocular Pressure (IOP) in the Study Eye [ Time Frame: Baseline, Week 12 ]
  2. IOP in the Study Eye [ Time Frame: Week 2 ]
  3. IOP in the Study Eye [ Time Frame: Week 6 ]
  4. IOP in the Study Eye [ Time Frame: Week 12 ]

Secondary Outcome Measures :
  1. Change from Baseline in IOP in the Study Eye [ Time Frame: Baseline, Week 2, Week 6 ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

-Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment.

Exclusion Criteria:

  • Previous enrollment in another Allergan Bimatoprost SR Study.
  • Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye
  • Anticipated need for laser eye surgery in either eye within the first 52 weeks of the study duration
  • History of glaucoma surgery
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02247804


Contacts
Contact: Clinical Trial Registry Team 877-277-8566 IR-CTRegistration@Allergan.com

  Show 196 Study Locations
Sponsors and Collaborators
Allergan
Investigators
Study Director: Margot Goodkin Allergan
More Information

Additional Information:
Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT02247804     History of Changes
Other Study ID Numbers: 192024-091
2014-003037-26 ( EudraCT Number )
First Posted: September 25, 2014    Key Record Dates
Last Update Posted: June 19, 2017
Last Verified: June 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Hypertension
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Timolol
Bimatoprost
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents